Lixte Biotechnology Holdings, Inc (LIXT)

Etorro trading 970x250
Lixte Biotechnology Holdings, Inc (LIXT) Logo

About Lixte Biotechnology Holdings, Inc

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures, which might be useful in the treatment of cancers, and vascular and metabolic diseases; and LB-200 series for the treatment of chronic hereditary diseases, such as Gaucher’s disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; pharmacologic study with the National Cancer Institute; and clinical research support agreement with City of Hope National Medical Center to carry out a Phase 1b clinical trial of its LB-100, a protein phosphatase inhibitor for small cell lung cancer. The company was incorporated in 2005 and is based in East Setauket, New York. Address: 248 Route 25A, No. 2, East Setauket, NY, United States, 11733

Lixte Biotechnology Holdings, Inc News and around…

Latest news about Lixte Biotechnology Holdings, Inc (LIXT) common stock and company :

Lixte Biotechnology Announces Filing of First Patent Application Resulting from Collaboration with the Netherlands Cancer Institute and the Oncode Institute to Identify the Most Promising Drug Combinations for Lead Clinical Compound, LB-100
12 Jan, 2022 Yahoo! Finance

PASADENA, CA, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) reported that its the recent collaboration with the Netherlands Cancer Institute (NKI), Amsterdam, one of the world’s leading comprehensive cancer centers, and Stichting Oncode Institute (Oncode Institute), Utrecht, a major independent cancer research center, has led to an initial joint patent application covering LB-100 combination therapy with one of several other investigational compounds. Lixte,

60 Biggest Movers From Yesterday
11 Jan, 2022 FinancialContent

Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday. Zynga Inc. (NASDAQ: ZNGA) ...

The Week Ahead In Biotech (Jan 10-15): JPMorgan Healthcare Conference Front And Center, Preannouncements Keep Coming
10 Jan, 2022 FinancialContent

Biotech stocks came under selling pressure along with the broader market, as rate hike fears seized Wall Street. The news flow, however, ...

12 Health Care Stocks Moving In Friday's Pre-Market Session
07 Jan, 2022 FinancialContent

Gainers Absci (NASDAQ:ABSI) shares increased by 51.5% to $9.3 during Friday's pre-market session. The market value ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session
06 Jan, 2022 FinancialContent

Gainers Freeline Therapeutics (NASDAQ:FRLN) stock increased by 58.1% to $3.1 during Thursday's pre-market session. ...

23 Stocks Moving in Thursday's Pre-Market Session
06 Jan, 2022 FinancialContent

Gainers Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) rose 54.3% to $0.9490 in pre-market trading after declining more than ...

50 Biggest Movers From Yesterday
06 Jan, 2022 FinancialContent

Gainers Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) shares surged 63.7% to settle at $2.21 on Wednesday after the company ...

12 Health Care Stocks Moving In Wednesday's Intraday Session
05 Jan, 2022 FinancialContent

Gainers Lixte Biotech Holdings (NASDAQ:LIXT) stock increased by 70.4% to $2.3 during Wednesday's regular session. ...

Dow Inches Higher as Tech Weighs on Nasdaq
05 Jan, 2022 FinancialContent

The Dow Jones Industrial Average is up a modest 56 points midday. Both the S&P 500 Index and Nasdaq Composite remain in the red, though, as semiconductor and tech stocks struggle.

See Why Lixte Biotech Shares Trading At Over 100%?
05 Jan, 2022 FinancialContent

In preclinical studies,Lixte Biotechnology Holdings Inc's(NASDAQ: LIXT) lead clinical compound, LB-100,increased ...

Lixte Biotechnology Stock Surges on Positive Data
05 Jan, 2022 Yahoo! Finance

By Sam Boughedda

Lixte Biotechnology’s LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Responsive (“Hot”) Tumors
05 Jan, 2022 Yahoo! Finance

Outside research shows that in models of colorectal, triple-negative breast and pancreatic cancer, LB-100 induces molecular changes that render the cancers more vulnerable to immunotherapy PASADENA, CA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, announced today that in preclinical studies its lead clinical compound, LB-100, a protein phosphatase

12 Health Care Stocks Moving In Thursday's After-Market Session
30 Dec, 2021 FinancialContent

Gainers Kiora Pharmaceuticals (NASDAQ:KPRX) shares rose 14.7% to $1.95 during Thursday's after-market session. At the close, Kiora ...

12 Health Care Stocks Moving In Friday's After-Market Session
03 Dec, 2021 FinancialContent

Gainers Lixte Biotech Holdings (NASDAQ:LIXT) stock increased by 22.13% to $1.49 during Friday's after-market session. The market ...

LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THAT ENROLLMENT HAS RESUMED IN NATIONAL CANCER INSTITUTE’S TRIAL TO DETERMINE ABILITY OF LIXTE COMPOUND LB-100 TO ENTER RECURRENT, MALIGNANT BRAIN TUMORS
22 Nov, 2021 Yahoo! Finance

PASADENA, CA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced that the National Cancer Institute (NCI) has resumed enrolling patients into their pharmacologic study of the ability of Lixte’s lead compound, LB-100, to enter the brain and penetrate recurrent, malignant brain tumors, in patients where surgical removal of their cancer is indicated. After enrolling two patients in the study, enrollment was suspended in 2020 due to COVID-19 restrictions. T

Lixte Biotechnology to Discuss its Collaboration with Leading European Cancer Centers at the Benzinga Global Small Cap Conference on October 28
20 Oct, 2021 Yahoo! Finance

Studies to use genome wide functional genetic techniques to identify effective drug combinations and new drug targets for its lead clinical compound, LB-100 PASADENA, CA, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will present at the Benzinga Global Small Cap Conference being held virtually October 27-28, 2021. Event and Registration: Benzinga G

Lixte Biotechnology Announces Collaboration with Netherlands Cancer Institute (Amsterdam) and Oncode Institute (Utrecht) to Identify the Most Promising Drug Combinations for its Lead Clinical Compound, LB-100, for Cancer Treatment
13 Oct, 2021 Yahoo! Finance

PASADENA, CA, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced entry into a collaboration with the Netherlands Cancer Institute, Amsterdam (NKI) , one of the world’s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent cancer research center, to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific m

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
08 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
07 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
06 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
05 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

We Think Lixte Biotechnology Holdings (NASDAQ:LIXT) Can Afford To Drive Business Growth
24 Sep, 2021 Yahoo! Finance

We can readily understand why investors are attracted to unprofitable companies. For example, although...

The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
22 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
21 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Lixte's LB-100 Blocks Behavioral Sensitization In Animal Models
17 Aug, 2021 FinancialContent

Lixte Biotechnology Holdings Inc(NASDAQ: LIXT) has announced additional results from preclinical studies of its lead clinical ...

Lixte Biotechnology’s LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine Addiction
17 Aug, 2021 FinancialContent
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
05 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

12 Health Care Stocks Moving In Tuesday's After-Market Session
03 Aug, 2021 FinancialContent

Gainers Cerus (NASDAQ:CERS) shares increased by 15.98% to $5.95 during Tuesday's after-market session. Today's trading volume for ...

Lixte Biotechnology Holdings, Inc (LIXT) is a NASDAQ Common Stock listed in , ,

970x250